{
    "eid": "2-s2.0-85150314244",
    "title": "\u201cWearing-off\u201d efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials",
    "cover-date": "2023-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Neurology (clinical)",
            "@code": "2728",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "CGRP monoclonal antibodies",
        "effect",
        "migraine prevention",
        "prophylaxis",
        "Wearing-off efficacy"
    ],
    "authors": [
        "Thanin Asawavichienjinda",
        "Seelwan Sathitratanacheewin",
        "Ronpichai Chokesuwattanaskul"
    ],
    "citedby-count": 0,
    "ref-count": 34,
    "ref-list": [
        "Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS)",
        "Migraine progression: a systematic review",
        "The International Classification of Headache Disorders, 3rd edition",
        "Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials",
        "The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice",
        "Anti-CGRP monoclonal antibodies: the next era of migraine prevention?",
        "European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention",
        "A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody",
        "New trends in migraine pharmacology: targeting calcitonin gene-related peptide (CGRP) with monoclonal antibodies",
        "Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations",
        "Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe",
        "Wearing off effect of onabotulinumtoxina near the end of treatment cycle for chronic migraine: a 4-year clinical experience",
        "OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine",
        "Wearing off response to onabotulinumtoxina in chronic migraine: analysis in a series of 193 patients",
        "Calcitonin gene-related peptide (CGRP) monoclonal antibody (MAB) wear-off phenomenon in the treatment of migraine",
        "Real-world patient experience with erenumab for the preventive treatment of migraine",
        "The aimovig \u201cwear-off\u201d: A retrospective review",
        "wearing-off effect\u201d seen in quarterly or monthly dosing of fremanezumab: subanalysis of a randomized long-term study",
        "Galcanezumab provides consistent efficacy throughout the dosing interval among patients with episodic and chronic migraine: a post hoc analysis",
        "Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures",
        "Quarterly administration of fremanezumab does not show \u201cwearing off\u201d effect during third month after injection (P2.10-013)",
        "Does \u201cwearing off\u201d of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "Meta-analysis in clinical trials",
        "Measuring inconsistency in meta-analyses",
        "Publication bias in clinical research",
        "Graphical displays for meta-analysis: An overview with suggestions for practice",
        "No evidence of wearing off effect for fremanezumab treatment in chronic and episodic migraine patients with inadequate response to 2\u20134 prior classes of migraine preventive medications",
        "Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial",
        "Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial",
        "Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial",
        "Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial",
        "Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study",
        "Power analysis for random-effects meta-analysis"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60002620",
        "affilname": "Faculty of Medicine, Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
        "affiliation-country": "Thailand"
    },
    "funding": []
}